Evidence map›Paper›PMID 36795117›Full record

ArticleAnnals of hematology2023

Impact of gemtuzumab ozogamicin consolidation on hematopoietic stem cells (HSCs) mobilization in AML: analysis of 20 patients.

Salvatore Perrone, Saveria Capria, Massimo Bernardi, Francesco Marchesi, Elettra Ortu La Barbera, Silvia Maria Trisolini, Clara Minotti, Mahnaz Shafii Bafti, Maria Cristina Scerpa, Antonino Mulé and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Salvatore PerroneHematology, Polo Universitario Pontino, "Sapienza", Via A. Canova S.M. Goretti Hospital, 04100, Latina, Italy. sperrone@hotmail.it.ORCID http://orcid.org/0000-0001-8196-0481
Saveria CapriaHaematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Massimo BernardiUniversity Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Francesco MarchesiHematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (I.F.O.), Rome, Italy.
Elettra Ortu La BarberaHematology, Polo Universitario Pontino, "Sapienza", Via A. Canova S.M. Goretti Hospital, 04100, Latina, Italy.
Silvia Maria TrisoliniHaematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Clara MinottiHaematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Mahnaz Shafii BaftiDepartment of Immunohematology and Transfusional Medicine, AOUP Umberto I, Rome, Italy.
Maria Cristina ScerpaHematology, Polo Universitario Pontino, "Sapienza", Via A. Canova S.M. Goretti Hospital, 04100, Latina, Italy.
Antonino MuléUOC Hematology and Oncology, Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy.
Fabio CiceriUniversity Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Maurizio MartelliHaematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Giuseppe CiminoHematology, Polo Universitario Pontino, "Sapienza", Via A. Canova S.M. Goretti Hospital, 04100, Latina, Italy.
Ospedale Santa Maria Goretti · ITSapienza University of Rome · ITVita-Salute San Raffaele University · ITIstituti Fisioterapici Ospitalieri · ITOspedale Vincenzo Cervello · ITPoliclinico Umberto I · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gemtuzumab ozogamicin (GO), is an anti-CD33 monoclonal antibody, approved for AML CD33 + , those patients with low and intermediate-risk who obtain a complete response may also be candidated for consolidation with autologous stem cell transplantation (ASCT). However, there are scant data on the mobilization of hemopoietic stem cells (HSC) after fractionated GO. We retrospectively studied data from five Italian centers and identified 20 patients (median age 54 years, range 29-69, 15 female, 15 NPM1

Indexed as

GemtuzumabHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteAdultAgedAntigens, CD34FemaleHematopoietic Stem CellsHumansMaleMiddle AgedRetrospective StudiesTransplantation, AutologousAntigens, CD34GemtuzumabAMLApheresisAutologous stem cell transplantation (ASCT)CD34 +Gemtuzumab ozogamicinNPM1

Identifiers

PMID36795117
OpenAlexW4321004662

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.